Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Jefferson Research

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pfizer Inc Issues FY 2013 Guidance In Line With Analysts' Estimates

Tuesday, 29 Jan 2013 07:00am EST 

Pfizer Inc announced that it is providing initial fiscal 2013 financial guidance, including a range for revenues of $56.2 billion to $58.2 billion and for adjusted diluted EPS of $2.20 to $2.30. The guidance reflects the benefit of a full-year contribution from Zoetis, partially offset by an unfavorable $0.02 adjusted and reported diluted EPS impact for Zoetis-related interest expense associated with the $3.65 billion debt offering and certain duplicative and other costs given the potential separation of Zoetis. Additionally, the Company's revenue guidance reflects the anticipated negative impact of approximately $4 billion due to product losses of exclusivity and the near-term expiration of certain co-promotion agreements. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $57.6 billion and EPS of $2.29 for fiscal 2013. 

Company Quote

0.21 +0.31%
19 Sep 2014